MiMédi Project

The MiMédi Project - Microtechnology for advanced therapy medicinal products (ATMPs) project for 4 years (2017 to 2021) of  13.6 M€ with funding from the European Regional Development Fund (€10 211 026) and BPI France (€584 000)) combines expertise in microtechnology and nanoscience to those in production of such future drugs to streamline and optimize ATMPs manufacturing  with new technical solutions. ATMPs have recently offered new treatments for patients in therapeutic stalemate. However, manufacturing these medicine cells require complex and expensive technologies
The project involves 10 partners (6 private companies, 3 academic partners and a transfer agency) around two complementary objectives:

  • The development of innovative production methods to validate a modular bio-reactor combining units representing the different stages of production of ATMPs. It would be an autonomous « white room » adapted to any type of laboratory. The project will reduce manufacturing costs and ATMPs can be locally produced.
  • The marketing of medicinal innovative drugs from "living" cells allowing news possibilities and treatment strategies as an alternative or in addition to current chemical drugs.

This project will allow:

  • The development of new processes in order to simplify production. The BMD team will use their skills including technological and conceptual of acoustics, vision, automation, microfluidics, nano - and microtechnologies.
  • The optimization of ATMPs manufacturing, by contribution of microtechnology abilities, to reduce manufacturing costs, increase the number and foster the access of these therapeutic strategies to the human evaluation phases.

These developments will facilitate the marketing of ATMPs to address public health problems.

Contact : Annie Frelet-Barrand